• MRT68921 and the AMPK-ULK1 Axis: Redefining Autophagy Inhibi

  2026-06-11

  Discover how MRT68921, a potent ULK1 kinase inhibitor, enables precise dissection of autophagy regulation beyond the AMPK activation model. This article provides unique insight into assay design, protocol decision points, and the latest paradigm shifts in autophagy research.

• β-Pseudouridine: Structural Dynamics and Epitranscriptomic C

  2026-06-11

  Explore how β-Pseudouridine, the C-glycoside isomer of uridine, uniquely stabilizes RNA structure, influences epitranscriptomic regulation, and impacts translational fidelity. This article delivers a deeper scientific analysis and practical guidance for RNA researchers.

• ZIF8-Based Nanotheranostics for Targeted TNBC Synergistic Th

  2026-06-10

  Li et al. introduce a folic acid–PEG–ZIF8 nanoplatform for triple-negative breast cancer (TNBC) therapy, integrating ciprofloxacin as a dual-function sonosensitizer and chemotherapeutic. The study demonstrates pH-responsive drug release, potent tumor targeting, and immune activation, offering new prospects for ultrasound-guided, multimodal TNBC treatment.

• Tivozanib (AV-951): Applied Workflows for VEGFR Inhibition

  2026-06-10

  Tivozanib (AV-951) redefines anti-angiogenic assay precision with its picomolar VEGFR-2 potency and superior selectivity. This article details actionable protocols, troubleshooting strategies, and translational tips for maximizing data quality in oncology research.

• Applied Immunometabolism with UK-5099: Protocols & Optimizat

  2026-06-09

  Harness the precision of UK-5099 (PF-1005023) to dissect mitochondrial metabolism in immune cells. This guide delivers advanced workflows and troubleshooting tips grounded in recent protocol innovations, empowering reproducible immunometabolic research.

• LEE011 Succinate: Applied CDK Inhibition for Cancer Research

  2026-06-09

  Harness the precision of Ribociclib succinate (LEE011 succinate) as a selective CDK inhibitor to drive robust cell cycle and antineoplastic workflows in cancer research. This guide delivers actionable protocol enhancements, troubleshooting strategies, and integrates the latest biomarker insights to elevate assay reproducibility and data depth.

• Cefotaxime in Bacterial Evolution Studies: Beyond Resistance

  2026-06-08

  Discover how Cefotaxime, a third-generation cephalosporin antibiotic, advances research on bacterial adaptation and gene transfer. This article uniquely explores its role in dissecting evolutionary pressures and horizontal gene transfer in complex infection models.

• LMO2–LDB1 Complex Drives AML Progression: Mechanistic Insigh

  2026-06-08

  This study uncovers the crucial oncogenic role of the LMO2–LDB1 transcriptional complex in acute myeloid leukemia (AML). By dissecting the molecular mechanisms and experimental perturbations of LMO2 and LDB1, the research highlights new avenues for targeting key protein interactions in AML therapy.

• SIS3 (Smad3 Inhibitor): Mechanistic Insights for Translation

  2026-06-07

  Explore how SIS3, a potent Smad3 inhibitor, enables high-precision modulation of the TGF-β signaling pathway for translational fibrosis and osteoarthritis research. This article uniquely dissects SIS3’s mechanistic impact on molecular assay design and practical experimental outcomes.

• SB 431542: ALK5 Inhibitor for Precision TGF-β Pathway Resear

  2026-06-06

  SB 431542 enables targeted inhibition of ALK5 within the TGF-β pathway, supporting reproducible modulation of cell proliferation, immune response, and fibrosis in both cellular and in vivo studies. This advanced inhibitor, supplied by APExBIO, is indispensable for dissecting Smad2 phosphorylation and anti-tumor immunology with quantifiable rigor.

• Captopril: ACE Inhibitor Benchmarks and Translational Insigh

  2026-06-05

  Captopril is a well-characterized ACE inhibitor with an IC50 of 6 nM, validated for antihypertensive and anticancer research. Its precise mechanism, high purity, and robust solubility profile support reproducible results in cardiovascular and translational oncology workflows.

• Pioglitazone: PPARγ Agonist Workflows for Inflammatory and M

  2026-06-05

  Pioglitazone, a selective PPARγ agonist from APExBIO, enables researchers to dissect insulin resistance, modulate macrophage polarization, and protect against inflammation in complex disease models. This guide translates recent mechanistic breakthroughs into actionable protocols and troubleshooting strategies for metabolic and immune modulation research.

• HDAC6-Driven α-Tubulin Lactylation Links Metabolism to Micro

  2026-06-04

  This study identifies HDAC6 as a principal enzyme catalyzing reversible lactylation of α-tubulin at lysine 40, revealing a novel metabolic regulation of microtubule dynamics. These findings provide new mechanistic insight into how cellular lactate influences cytoskeletal behavior, with implications for neurobiology and cell cycle research.

• Bestatin (Ubenimex): Precision in Aminopeptidase Assays & MD

  2026-06-04

  Bestatin (Ubenimex) delivers unrivaled specificity for dissecting aminopeptidase-mediated pathways, enabling researchers to decode multidrug resistance and apoptosis mechanisms in cancer models. Practical guidance on experimental workflows, troubleshooting, and advanced applications positions this APExBIO reagent as a cornerstone for protease and MDR research.

• Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4

  2026-06-03

  Explore how Morin, a natural flavonoid, uniquely modulates podocyte mitochondrial function through AMPD inhibition. This in-depth article reveals mechanistic insights and practical assay considerations that set Morin apart in diabetes and kidney research.

15157 records 1/1011 page Next 12345 下5页 Last page